Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF MAY 13, 2021 SAM #7103
SPECIAL NOTICE

65 -- In situ hybridization assay for detection and amplification of unique RNA targets within intact cells

Notice Date

5/11/2021 8:51:27 AM
 

Notice Type

Special Notice
 

NAICS

325413 — In-Vitro Diagnostic Substance Manufacturing
 

Contracting Office

NATIONAL INSTITUTES OF HEALTH NIDCR BETHESDA MD 20892 USA
 

ZIP Code

20892
 

Solicitation Number

HHS-NIH-NIDCR-21-003588
 

Response Due

5/21/2021 1:00:00 PM
 

Archive Date

06/05/2021
 

Point of Contact

Jimmy L Sanders, Phone: 301-451-7873
 

E-Mail Address

sandersj@mail.nih.gov
(sandersj@mail.nih.gov)
 

Small Business Set-Aside

SBA Total Small Business Set-Aside (FAR 19.5)
 

Description

This notice is being published in accordance with Federal Acquisition Regulation (FAR) Part 5.101(a)(2) requiring the dissemination of information on proposed contract actions expected to exceed $15,000, but not expected to exceed $25,000. This is a notice of intent to award a sole source contract to Advance Cell Diagnostics and is not a request for competitive proposals.� This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold.� Contracts awarded using FAR Part 13�Simplified Acquisition Procedures and at a dollar value less than the simplified acquisition threshold are exempt from the requirements of FAR Part 6�Competition Requirements. Single-sole Source Determination: The determination by the Government to make a single-sole source is based upon the market research conducted as prescribed in FAR Part 10�Market Research, specifically the results of the market research concluded that this order is for in situ hybridization (ISH) performed by Advanced Cell Diagnostics, Inc (ACD).� ACD has designed probes that bind onto tissue sections and labels genes of interest.� Their proprietary RNAscope technology allows for little background and 400-fold increased detection sensitivity over conventional commercially available ISH. This technology enables in situ detection of RNA molecules as small as 300 base pairs, including degraded mRNA, enabling preservation of cellular and molecular context. As such, ACD has essentially become the standard technology used to detect gene expression on fixed tissue sections. Our research involves human bone tissue specimens primarily obtained from surgical waste. As such, these are rare and valuable specimens, many of which are years-to-decades old. Using any other company to perform ISH would not provide the desired sensitivity and would disrupt the continuity in our research. ACD is the only company that can accommodate all of the conditions needed for our research. ��ACD is needed as the source for the benefit of the government. Closing Statement: This notice is not a request for competitive proposals.� However, interested parties may identify their interest and capability to respond to this notice.� Responses to this notice shall contain sufficient information to establish the interested parties� bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.� A determination by the Government not to compete this proposed action based upon responses to this notice is solely within the discretion of the Government.� The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.�� 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment. (Aug 2020) All responses must be received by May 21, 2021 at 4:00 PM Eastern Time. �Responses may be submitted electronically to sandersj@mail.nih.gov NIDCR�6701 Democracy Blvd., DEM 1, Room 675 Bethesda, MD 20892 �Attention: Jimmy Sanders.� Fax responses will not be accepted. �All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.�
 

Web Link

SAM.gov Permalink
(https://beta.sam.gov/opp/a347605c76c5401f95bb62c3748aab49/view)
 

Place of Performance

Address: Bethesda, MD 20892, USA

Zip Code: 20892

Country: USA
 

Record

SN05997684-F 20210513/210511230053 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |